Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients.

AIM To elucidate the role of overexpressed polo-like kinase1 (PLK1) in hepatocellular carcinoma (HCC). METHODS We prospectively collected clinicopathological, immunohistochemical and semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) data from 135 HCC patients undergoing successful hepatectomy. The correlations between PLK1 mRNA expression and clinicopathologic variables were analyzed by Mann-Whitney U test. Prognostic factors were identified by univariate and multivariate analyses. RESULTS Immunohistochemical results showed overexpression of PLK1 was mainly found in tumor tissues compared with tumor-free tissue. A similar mRNA result was obtained by semi-quantitative RT-PCR. A total of 111 samples were positive for PLK1 mRNA expression. The positive expression was correlated with venous invasion, tumor nodules and Edmondson grade. Furthermore, 1, 3, 5-year survival rates in the positive expression group were significantly lower than the negative control group. Multivariate analysis showed that positive PLK1 expression was an independent risk factor for HCC. CONCLUSION PLK1 could be a potential biomarker for diagnosis and therapy for HCC.

• Publication year

  2009

• Venue

  World Journal of Gastroenterology

• Publication date

  2009-09-07

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3748/WJG.15.4177PMID 19725153PMCID PMC2738815
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Surgical treatment for hepatocellular carcinoma.

  2011cited by this paper
• High expression levels of cyclin B1 and Polo-like kinase 1 in ectopic endometrial cells associated with abnormal cell cycle regulation of endometriosis.

  2009cited by this paper
• Overexpression of PLK1 is associated with poor survival by inhibiting apoptosis via enhancement of survivin level in esophageal squamous cell carcinoma

  2009cited by this paper
• The function of APC/CCdh1 in cell cycle and beyond

  2009cited by this paper
• Silencing of Polo-Like Kinase (Plk) 1 via siRNA Causes Inhibition of Growth and Induction of Apoptosis in Human Esophageal Cancer Cells

  2008cited by this paper
• Aberrant Polo-Like Kinase 1-Cdc25A Pathway in Metastatic Hepatocellular Carcinoma

  2008cited by this paper
• Bora and the Kinase Aurora A Cooperatively Activate the Kinase Plk1 and Control Mitotic Entry

  2008cited by this paper
• Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles.

  2008cited by this paper
• Rational combinations of siRNAs targeting Plk1 with breast cancer drugs

  2007cited by this paper
• Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection.

  2007cited by this paper
• A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma.

  2007cited by this paper
• Identification of Candidate Biomarkers for Hepatocellular Carcinoma Through Pre-Cancerous Expression Analysis in an HBx Transgenic Mouse

  2007cited by this paper
• Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?

  2006cited by this paper
• Oncogenic effect of Polo-like kinase 1 expression in human gastric carcinomas.

  2006cited by this paper
• Expression patterns of polo‐like kinase 1 in human gastric cancer

  2006cited by this paper
• Self-regulated Plk1 recruitment to kinetochores by the Plk1-PBIP1 interaction is critical for proper chromosome segregation.

  2006cited by this paper
• Expression of Polo-Like Kinase 1 (PLK1) Protein Predicts the Survival of Patients with Gastric Carcinoma

  2006cited by this paper
• Overexpression of Polo-Like Kinase 1 (PLK1) and Chromosomal Instability in Bladder Cancer

  2006cited by this paper
• Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.

  2006cited by this paper
• Inhibitory effect of Polo-like kinase 1 depletion on mitosis and apoptosis of gastric cancer cells.

  2006cited by this paper
• Expression of polo-like kinase (PLK1) in non-Hodgkin's lymphomas

  2005cited by this paper
• Overexpression of Polo-Like Kinase 1 Is a Common and Early Event in Pancreatic Cancer

  2005cited by this paper
• Surgical treatment of hepatocellular carcinoma.

  2005cited by this paper
• Polo-like kinase 1 expression is a prognostic factor in human colon cancer.

  2005cited by this paper
• Expression of Polo-Like Kinase (PLK1) in non-Hodgkin's lymphomas

  2005cited by this paper
• Polo-like kinase 1 inactivation following mitotic DNA damaging treatments is independent of ataxia telangiectasia mutated kinase.

  2004cited by this paper
• Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas

  2004cited by this paper
• Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma

  2004cited by this paper
• Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer.

  2004cited by this paper
• Polo-like kinase 1 overexpression is an early event in the progression of papillary carcinoma

  2004cited by this paper
• Polo‐like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades

  2004cited by this paper
• A role for Plk1 phosphorylation of NudC in cytokinesis.

  2003cited by this paper
• Active cyclin B1–Cdk1 first appears on centrosomes in prophase

  2003cited by this paper
• Polo‐like kinase 1 (PLK1) is overexpressed in primary colorectal cancers

  2003cited by this paper
• Molecular viral oncology of hepatocellular carcinoma

  2003cited by this paper
• Plk1 promotes nuclear translocation of human Cdc25C during prophase

  2002cited by this paper
• Expression of polo‐like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease

  2002cited by this paper
• Irregular regeneration of hepatocytes is an important factor in the hepatocarcinogenesis of liver disease

  2001cited by this paper
• Polo-like kinase (PLK) expression in endometrial carcinoma.

  2001cited by this paper
• Increased Human Polo-Like Kinase-1 Expression in Gliomas

  2001cited by this paper
• Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer.

  2000cited by this paper
• Polo-like kinase-1 is a target of the DNA damage checkpoint

  2000cited by this paper
• Prognostic value of pololike kinase expression in melanomas.

  2000cited by this paper
• Blood lead level and dental caries.

  2000cited by this paper
• Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck.

  1999cited by this paper
• Prognostic significance of polo-like kinase expression in esophageal carcinoma.

  1999cited by this paper
• Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase.

  1997cited by this paper
• Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer

  1997cited by this paper

• In Silico Network Toxicology, Molecular Docking, and Multi‐Level Bioinformatics Reveal Methyl Eugenol‐Induced Hepatocellular Carcinoma Mechanisms in Humans

  2025cites this paper
• Onvansertib and Navitoclax Combination as a New Therapeutic Option for Mucinous Ovarian Carcinoma

  2025cites this paper
• PLK1 and PARP positively correlate in Middle Eastern breast cancer and their combined inhibition overcomes PARP inhibitor resistance in triple negative breast cancer

  2024cites this paper
• Comprehensive analysis identifies YKT6 as a potential prognostic and diagnostic biomarker in lung adenocarcinoma

  2024cites this paper
• PLK1 inhibition leads to mitotic arrest and triggers apoptosis in cholangiocarcinoma cells

  2024cites this paper
• Drug resistance mechanisms and treatment strategies mediated by Ubiquitin-Specific Proteases (USPs) in cancers: new directions and therapeutic options

  2024cites this paper
• RPL27 contributes to colorectal cancer proliferation and stemness via PLK1 signaling

  2023cites this paper
• Increased hsa-miR-100-5p Expression Improves Hepatocellular Carcinoma Prognosis in the Asian Population with PLK1 Variant rs27770A>G

  2023cites this paper
• Development and validation of multi-omic prognostic signature of anoikis-related genes in liver hepatocellular carcinoma

  2023cites this paper
• BI6727 and GSK461364A, potent PLK1 inhibitors induce G2/M arrest and apoptosis against cholangiocarcinoma cell lines.

  2023cites this paper
• Characteristics and prognostic significance of polo‐like kinase‐1 (PLK1) expression in breast cancer

  2023cites this paper
• Therapeutic Potential of Mitotic Kinases’ Inhibitors in Cancers of the Gastrointestinal System

  2022cites this paper
• Polo-like kinase 1 is related with malignant characteristics and inhibits macrophages infiltration in glioma

  2022cites this paper
• Expression of FOXM1 and PLK1 predicts prognosis of patients with hepatocellular carcinoma

  2022cites this paper
• Comprehensive kinomic study via a chemical proteomic approach reveals kinome reprogramming in hepatocellular carcinoma tissues

  2021cites this paper
• Characterization of diagnostic and prognostic significance of cell cycle-linked genes in hepatocellular carcinoma

  2021cites this paper
• Polo-like kinase 1 (PLK1) signaling in cancer and beyond.

  2021cites this paper
• Cytokinesis regulators as potential diagnostic and therapeutic biomarkers for human hepatocellular carcinoma

  2021cites this paper
• Polo-like kinase 1 as a promising diagnostic biomarker and potential therapeutic target for hepatocellular carcinoma

  2020cites this paper
• Transcriptional analysis and differentially expressed gene screening of spontaneous liver tumors in CBA/CaJ mice.

  2020cites this paper
• Novel molecular targets in hepatocellular carcinoma

  2020cites this paper
• Discovery of methyl 3-((2-((1-(dimethylglycyl)-5-methoxyindolin-6-yl)amino)-5-(trifluoro-methyl) pyrimidin-4-yl)amino)thiophene-2-carboxylate as a potent and selective polo-like kinase 1 (PLK1) inhibitor for combating hepatocellular carcinoma.

  2020cites this paper
• Bioinformatics analysis to identify the key genes affecting the progression and prognosis of hepatocellular carcinoma

  2019cites this paper
• USP7 is a novel Deubiquitinase sustaining PLK1 protein stability and regulating chromosome alignment in mitosis

  2019cites this paper
• MicroRNA-1181 supports the growth of hepatocellular carcinoma by repressing AXIN1.

  2019cites this paper
• Clinicopathological and prognostic implications of polo-like kinase 1 expression in colorectal cancer: A systematic review and meta-analysis.

  2019cites this paper
• Hsa-let-7b inhibits cell proliferation by targeting PLK1 in HCC.

  2018cites this paper
• Knockdown of PLK1 inhibits invasion and promotes apoptosis in glioma cells through regulating autophagy.

  2018cites this paper
• Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer.

  2018cites this paper
• Hepatitis B virus X protein promotes DNA damage propagation through disruption of liver polyploidization and enhances hepatocellular carcinoma initiation

  2018cites this paper
• Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma

  2018cites this paper
• Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.

  2017cites this paper
• Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic “dual-hit” option

  2017cites this paper
• Protéine HBx du virus de l'hépatite B : impacts sur la polyploïdisation hépatique au cours du développement et de la maladie du foie

  2017cites this paper
• Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1

  2017cites this paper
• The clinical and prognostic value of polo-like kinase 1 in lung squamous cell carcinoma patients: immunohistochemical analysis

  2017cites this paper
• Augmented expression of Polo-like kinase 1 is a strong predictor of shorter cancer-specific overall survival in early stage breast cancer at 15-year follow-up

  2016cites this paper
• Prognostic significance of p 27 Kip 1 , PLK 1 aberrant expression in esophageal squamous cell carcinoma

  2016cites this paper
• PLK1, A Potential Target for Cancer Therapy

  2016cites this paper
• Volasertib suppresses the growth of human hepatocellular carcinoma in vitro and in vivo.

  2016cites this paper
• RB/PLK1-dependent induced pathway by SLAMF3 expression inhibits mitosis and control hepatocarcinoma cell proliferation

  2016influential citation
• Cross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications

  2016cites this paper
• NCAPG2 promotes tumour proliferation by regulating G2/M phase and associates with poor prognosis in lung adenocarcinoma

  2016cites this paper
• Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer

  2015cites this paper
• Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines.

  2015cites this paper
• Unconventional Functions of Mitotic Kinases in Kidney Tumorigenesis

  2015cites this paper
• Enhancements of hyperthermia sensitivity by novel molecular targets of heat shock transcription factor 1-related proteins in human cancer cells

  2015influential citation
• Drug-Related Genomics in Cancer and Immunological Diseases

  2014cites this paper
• PLK1 expression and BI 2536 effects in childhood acute lymphoblastic leukemia

  2014cites this paper
• A 3′UTR polymorphism modulates mRNA stability of the oncogene and drug target Polo-like Kinase 1

  2014cites this paper
• High Expression of Polo-Like Kinase 1 Is Associated with Early Development of Hepatocellular Carcinoma

  2014cites this paper
• Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cells

  2013cites this paper
• Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in hepatocellular carcinoma

  2013cites this paper
• Inhibition of polo-like kinase 1 promotes hyperthermia sensitivity via inactivation of heat shock transcription factor 1 in human retinoblastoma cells.

  2013cites this paper
• Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels.

  2012cites this paper
• PLK1 gene suppresses cell invasion of undifferentiated thyroid carcinoma through the inhibition of CD44v6, MMP-2 and MMP-9

  2012cites this paper
• Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells

  2012cites this paper
• Overexpression of polo-like kinase 1 and its clinical significance in human non-small cell lung cancer.

  2012cites this paper
• Clinicopathological significance of Polo-like kinase 1 (PLK1) expression in human malignant glioma.

  2012cites this paper
• Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma.

  2012cites this paper
• Hepatocellular carcinoma: important biomarkers and their significance in molecular diagnostics and therapy.

  2012cites this paper
• Polo-like kinase 1 as target for cancer therapy

  2012cites this paper
• Polo-like kinase 1 contributes to the tumorigenicity of BEL-7402 hepatoma cells via regulation of Survivin expression.

  2011cites this paper
• Polo‐like kinase 1 (Plk1) in cutaneous T‐cell lymphoma

  2011cites this paper
• verexpression of polo-like kinase 1 and its clinical significance in human on-small cell lung cancer

  2011cites this paper
• Polo-like kinase 1 is a potential therapeutic target in human melanoma.

  2011cites this paper
• Induction of antitumor immunity using dendritic cells electroporated with Polo‐like kinase 1 (Plk1) mRNA in murine tumor models

  2011cites this paper
• Gene signatures in hepatocellular carcinoma (HCC).

  2011cites this paper
• Intravenous liposomal delivery of the short hairpin RNAs against Plk1 controls the growth of established human hepatocellular carcinoma

  2011cites this paper
• High-throughput screens in diploid cells identify factors that contribute to the acquisition of chromosomal instability

  2010cites this paper
• RNAi phenotype profiling of kinases identifies potential therapeutic targets in Ewing's sarcoma

  2010cites this paper